Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Clinical Data For Tesetaxel, A Leading Oral Taxane, Show Anticancer Activity And Acceptable Safety In Ongoing Study
Genta Incorporated (OTCBB: GNTA.OB) announced preliminary results from its ongoing clinical study of tesetaxel, a leading oral taxane in the Company"s investigational drug portfolio. The new data show a favorable safety profile with a low incidence of serious adverse events, along with objective responses that have been observed at less than the maximally tolerated dose (MTD). The data are featured in a presentation today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.

$1 Million For Memory Research Awarded To UTSA Psychologist
University of Texas at San Antonio Assistant Professor of Psychology Rebekah Smith has been awarded a five-year, $1 million grant from the National Institutes of Health to study adult memory. To conduct the research, beginning in July, Smith will be recruiting younger adult volunteers aged 18-30 and older adults, aged 60 and above.
News of the day
Morning People And Night Owls Show Different Brain Function: University Of Alberta Study
Scientists at the University of Alberta have found that there are significant differences in the way our brains function depending on whether we"re early risers or night owls.
Diagnostics

Elekta Receives FDA 510 (k) Clearance For Monaco VMAT Treatment Planning Solution

Elekta (STO:EKTAB) has received FDA 510(k) clearance for the VMAT (Volumetric Modulated Arc Therapy) enhancement to Monaco®, treatment planning solution. Monaco treatment planning system, introduces a set of tools to make the treatment planning process easier, more straightforward and clinically reliable. For the clinicians this gives the flexibility and control needed for complex treatment. For the clinic administrator it provides reduced planning time and increased clinical throughput. "We are extremely proud and very pleased to receive clearance to add this VMAT technique to Monaco in the U.S. market," said Rob Cessac, Product Manager for Elekta CMS Software. "Our continued support and development of leading approaches to cancer treatment promises to create a positive future for clinicians and patients." The biologically-based Monaco IMRT (Intensity Modulated Radiotherapy) treatment planning system features constrained optimization and dose calculation algorithms and help reduce the time needed to optimize IMRT plans. Monaco has been available for use clinically for the past two years for step-and-shoot IMRT planning. The product was developed in cooperation with Eberhard Karls University Tuebingen in Germany. For the latest Monaco with VMAT news, visit http://www.elekta.com. Elekta


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009